Computer-based assessment of cognitive functions in brain tumor patients
- 260 Downloads
NeuroCogFX is a short yet comprehensive computer-based neuropsychological battery of tests developed to investigate neurological patients for cognitive dysfunction after potentially neurotoxic therapy. NeuroCogFX had been standardized in a group of 242 healthy controls (Fliessbach et al., Fortschr Neurol Psychiatr 74:643–650, 2006). The present study was conducted to assess the practicability, reliability, and validity of NeuroCogFX in brain tumor patients without active disease after tumor-directed therapy. To evaluate its validity, neuropsychological testing with NeuroCogFX was completed parallel to a battery of established neuropsychological tests in 54 patients with different types of brain tumors and without active disease for at least 6 months. Retest reliability was assessed in a different sample of 49 patients with gliomas. Results showed good practicability with a median test duration of 28 min (range 16–51 min). Most subtests showed medium-sized retest reliability in healthy controls and tumor patients, with the exception of the 2-back test and reaction time measures in tumor patients. Convergent validity was confirmed for the domains psychomotor speed, verbal memory, and verbal short-term memory. NeuroCogFX enables serial scientific neuropsychological assessment of brain tumor patients. It can be carried out within a short period of time by non-academic personnel and is therefore applicable to large cohorts, e.g., within clinical trials.
KeywordsNeuropsychological test Neurotoxicity Computerized (computer-based, computer-assisted) testing Follow-up examination
Conflict of Interest Statement
With kind permission of the University of Bonn Medical Centre NeuroCogFX is marketed by three of the authors (C. Hoppe, K. Fliessbach, C. Helmstaedter).
- 7.Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW, Dekker AW, Jolles J, Slotman BJ, Struikmans H, Taphoorn MJ (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360:1361–1368CrossRefPubMedGoogle Scholar
- 11.Corn BW, Yousem DM, Scott CB, Rotman M, Asbell SO, Nelson DF, Martin L, Curran WJ Jr (1994) White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83–02). Cancer 74:2828–2835CrossRefPubMedGoogle Scholar
- 17.Brown PD, Buckner JC, O’Fallon JR, Iturria NL, Brown CA, O’Neill BP, Scheithauer BW, Dinapoli RP, Arusell RM, Curran WJ, Abrams R, Shaw EG (2003) Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 21:2519–2524CrossRefPubMedGoogle Scholar
- 21.Zimmermann P, Fimm B (1997) Test for Assessing Attentional Performance (TAP). Version 1.5. Psytest. Herzogenrath, GermanyGoogle Scholar
- 22.Brickenkamp R, Zillmer E (1998) The d2 Test of Attention. Hogrefe & Huber Publishers, Seattle, WAGoogle Scholar
- 23.Reitan RM (1992) Trail Making Test: manual for administration and scoring. Reitan Neuropsychology Laboratory, Tucson, AZGoogle Scholar
- 24.Haerting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J (2000) Wechsler Memory Scale-Revised (WMS-R) (German Version). Huber, Bern, SwitzerlandGoogle Scholar
- 25.Rey A (1964) L’examen clinique en psychologie. Presses Universitaires de France, ParisGoogle Scholar
- 26.Rey A (1959) Manuel du test de copie d’une figure complexe de A. Rey. Les Editions du Centre de Psychologie Appliquée, ParisGoogle Scholar
- 27.Kessler J, Denzler P, Markowitsch HJ (1988) Demenz-Test. Germany, Beltz Test, GoettingenGoogle Scholar